A Prospective, Single-Arm, Open-label Study to Investigate the Efficacy and Safety of Intravesical Injection of Botulinum Toxin Type-A (500 Units Dysport) for the Management of Idiopathic Overactive Bladder Syndrome.
Latest Information Update: 27 Jul 2020
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Overactive bladder
- Focus Therapeutic Use
Most Recent Events
- 26 Jul 2020 Status changed from recruiting to completed.
- 24 May 2011 New trial record